{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T04:47:05Z","timestamp":1769834825192,"version":"3.49.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5,1]]},"abstract":"<jats:sec>\n<jats:title>Objectives<\/jats:title>\n<jats:p>Sodium-glucose cotransporter 2 inhibitors (SGLT2i) modulate lipid metabolism and improve cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). The exact cardioprotective mechanism of SGLT2i is unclear. We evaluated the effects of SGLT2i on postprandial lipids, lipoprotein concentrations, glucose and fatty acids.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Design<\/jats:title>\n<jats:p>A placebo-controlled randomized, proof-of-concept study.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Fourteen male patients with T2DM on intensive insulin regimen were randomly and double-blind allocated to 12 weeks dapagliflozin (10 mg) or placebo. Postprandial effects were assessed with an 8-h standardized oral fat loading test.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Mean glycated A1c did not change by dapagliflozin, but the mean daily insulin dose was significantly reduced. Although dapagliflozin did not affect fasting or postprandial levels of glucose and insulin, it increased the postprandial levels of glucagon. While fasting levels of free fatty acids and beta-hydroxybutyrate (bHBA) were unchanged, dapagliflozin significantly increased the postprandial bHBA response. This was seen in the context of increased postprandial glucagon levels by dapagliflozin, without influencing postprandial insulin or glucose levels. Dapagliflozin did not affect fasting or postprandial plasma cholesterol and triglycerides nor postprandial inflammatory markers. Fasting apolipoprotein B48 was decreased without affecting the postprandial response. Markers of inflammation and vascular function did not change.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Treatment with dapagliflozin of patients with T2DM led to a reduction of fasting chylomicron remnants and increased postprandial ketone bodies compared to placebo suggesting enhanced hepatic fatty acid oxidation. The latter may have been caused by decreasing the insulin\u2013glucagon ratio. The beneficial clinical effects seen in the trials using dapagliflozin most likely are not due to effects on postprandial inflammation nor postprandial lipemia.<\/jats:p>\n<\/jats:sec>","DOI":"10.1530\/eje-21-1270","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T17:16:34Z","timestamp":1647882994000},"page":"597-605","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-7","source":"Crossref","is-referenced-by-count":5,"title":["Effects of dapagliflozin on postprandial lipid metabolism in type 2 diabetes mellitus"],"prefix":"10.1093","volume":"186","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3935-1233","authenticated-orcid":true,"given":"Benjamin","family":"Burggraaf","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Center for Endocrinology, Diabetes and Vascular Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine M C","family":"Pouw","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvador","family":"Fern\u00e1ndez Arroyo","sequence":"additional","affiliation":[{"name":"Departament de Medicina i Cirurgia, Unitat de Recerca Biom\u00e8dica, Universitat Rovira i Virgili, Tarragona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonie C","family":"van Vark-van der Zee","sequence":"additional","affiliation":[{"name":"Division of Pharmacology, Vascular and Metabolic Diseases, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gert-Jan M","family":"van de Geijn","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erwin","family":"Birnie","sequence":"additional","affiliation":[{"name":"Department of Statistics and Education, Franciscus Academy, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands"},{"name":"Department of Genetics, University Medical Center Groningen, Groningen University, Groningen, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannine","family":"Huisbrink","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen M","family":"van der Zwan","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wouter W","family":"de Herder","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Endocrinology, Erasmus Medical Center, Rotterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monique T","family":"Mulder","sequence":"additional","affiliation":[{"name":"Division of Pharmacology, Vascular and Metabolic Diseases, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick C N","family":"Rensen","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Castro Cabezas","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Center for Endocrinology, Diabetes and Vascular Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, the Netherlands"},{"name":"Department of Internal Medicine, Section of Endocrinology, Erasmus Medical Center, Rotterdam, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"bib1","series-title":"Diabetes Care","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","article-title":"Global Prevalence of Diabetes: estimates for the year 2000 and projections for 2030","volume":"27","author":"Wild","year":"2004","unstructured":"Wild SRoglic GGreen ASicree RKing H. Global Prevalence of Diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care2004271047\u20131053. (https:\/\/doi.org\/10.2337\/diacare.27.5.1047)10.2337\/diacare.27.5.1047"},{"key":"bib2","series-title":"New England Journal of Medicine","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1056\/NEJMoa1504347","article-title":"Excess mortality among persons with type 2 diabetes","volume":"373","author":"Tancredi","year":"2015","unstructured":"Tancredi MRosengren ASvensson AMKosiborod MPivodic AGudbj\u00f6rnsdottir SWedel HClements MDahlqvist SLind M. Excess mortality among persons with type 2 diabetes. New England Journal of Medicine20153731720\u20131732. (https:\/\/doi.org\/10.1056\/NEJMoa1504347)10.1056\/NEJMoa1504347"},{"key":"bib3","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","unstructured":"Emerging Risk Factors Collaboration, Sarwar NGao PSeshasai SRGobin RKaptoge SDi Angelantonio EIngelsson ELawlor DASelvin EDiabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet20103752215\u20132222. (https:\/\/doi.org\/10.1016\/S0140-6736(1060484-9)10.1016\/S0140-6736(10)60484-9"},{"key":"bib4","series-title":"New England Journal of Medicine","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1008862","article-title":"Diabetes mellitus, fasting glucose, and risk of cause-specific death","volume":"364","author":"Rao Kondapally Seshasai","year":"2011","unstructured":"Rao Kondapally Seshasai SKaptoge SThompson ADi Angelantonio EGao PSarwar NWhincup PHMukamal KJGillum RFHolme IDiabetes mellitus, fasting glucose, and risk of cause-specific death. New England Journal of Medicine2011364829\u2013841. (https:\/\/doi.org\/10.1056\/NEJMoa1008862)10.1056\/NEJMoa1008862"},{"key":"bib5","series-title":"Arteriosclerosis, Thrombosis, and Vascular Biology","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1161\/ATVBAHA.119.310961","article-title":"Diabetes mellitus and cardiovascular disease","volume":"39","author":"Schmidt","year":"2019","unstructured":"Schmidt AMDiabetes mellitus and cardiovascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology201939558\u2013568. (https:\/\/doi.org\/10.1161\/ATVBAHA.119.310961)10.1161\/ATVBAHA.119.310961"},{"key":"bib6","series-title":"BMJ","article-title":"Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials","volume":"343","author":"Boussageon","year":"2011","unstructured":"Boussageon RBejan-Angoulvant TSaadatian-Elahi MLafont SBergeonneau CKassai BErpeldinger SWright JMGueyffier FCornu C. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ2011343 d4169. (https:\/\/doi.org\/10.1136\/bmj.d4169)"},{"key":"bib7","series-title":"European Journal of Internal Medicine","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2017.04.017","article-title":"Interventions in type 2 diabetes mellitus and cardiovascular mortality \u2013 an overview of clinical trials","volume":"42","author":"Burggraaf","year":"2017","unstructured":"Burggraaf BCastro Cabezas M. Interventions in type 2 diabetes mellitus and cardiovascular mortality \u2013 an overview of clinical trials. European Journal of Internal Medicine2017421\u201315. (https:\/\/doi.org\/10.1016\/j.ejim.2017.04.017)10.1016\/j.ejim.2017.04.017"},{"key":"bib8","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1210\/jc.2009-0473","article-title":"Sodium glucose Cotransporter 2 inhibitors as a new treatment for diabetes mellitus","volume":"95","author":"Nair","year":"2010","unstructured":"Nair SWilding JPH. Sodium glucose Cotransporter 2 inhibitors as a new treatment for diabetes mellitus. Journal of Clinical Endocrinology and Metabolism20109534\u201342. (https:\/\/doi.org\/10.1210\/jc.2009-0473)10.1210\/jc.2009-0473"},{"key":"bib9","series-title":"Journal of Clinical Investigation","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","unstructured":"Ferrannini EMuscelli EFrascerra SBaldi SMari AHeise TBroedl UCWoerle HJ. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. Journal of Clinical Investigation2014124499\u2013508. (https:\/\/doi.org\/10.1172\/JCI72227)10.1172\/JCI72227"},{"key":"bib10","series-title":"New England Journal of Medicine","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","unstructured":"Zinman BWanner CLachin JMFitchett DBluhmki EHantel SMattheus MDevins TJohansen OEWoerle HJEmpagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine20153732117\u20132128. (https:\/\/doi.org\/10.1056\/NEJMoa1504720)10.1056\/NEJMoa1504720"},{"key":"bib11","series-title":"New England Journal of Medicine","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","unstructured":"Neal BPerkovic VMahaffey KWde Zeeuw DFulcher GErondu NShaw WLaw GDesai MMatthews DRCanagliflozin and cardiovascular and renal events in type 2 diabetes. New England Journal of Medicine2017377644\u2013657. (https:\/\/doi.org\/10.1056\/NEJMoa1611925)10.1056\/NEJMoa1611925"},{"key":"bib12","series-title":"New England Journal of Medicine","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","unstructured":"Wiviott SDRaz IBonaca MPMosenzon OKato ETCahn ASilverman MGZelniker TAKuder JFMurphy SADapagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine2019380347\u2013357. (https:\/\/doi.org\/10.1056\/NEJMoa1812389)10.1056\/NEJMoa1812389"},{"key":"bib13","series-title":"Lancet","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","unstructured":"Zelniker TAWiviott SDRaz IIm KGoodrich ELBonaca MPMosenzon OKato ETCahn AFurtado RHMSGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet201939331\u201339. (https:\/\/doi.org\/10.1016\/S0140-6736(1832590-X)10.1016\/S0140-6736(18)32590-X"},{"key":"bib14","series-title":"Postgraduate Medicine","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1080\/00325481.2019.1581971","article-title":"SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses","volume":"131","author":"Filippatos","year":"2019","unstructured":"Filippatos TDLiontos APapakitsou IElisaf MS. SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses. Postgraduate Medicine201913182\u201388. (https:\/\/doi.org\/10.1080\/00325481.2019.1581971)10.1080\/00325481.2019.1581971"},{"key":"bib15","series-title":"Clinica Chimica Acta: International Journal of Clinical Chemistry","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.cccn.2004.08.008","article-title":"Determination of apolipoprotein B-48 in serum by a sandwich ELISA","volume":"351","author":"Kinoshita","year":"2005","unstructured":"Kinoshita MKojima MMatsushima TTeramoto T. Determination of apolipoprotein B-48 in serum by a sandwich ELISA. Clinica Chimica Acta: International Journal of Clinical Chemistry2005351115\u2013120. (https:\/\/doi.org\/10.1016\/j.cccn.2004.08.008)10.1016\/j.cccn.2004.08.008"},{"key":"bib16","series-title":"Arteriosclerosis, Thrombosis, and Vascular Biology","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1161\/ATVBAHA.107.159749","article-title":"Leukocyte activation by triglyceride-rich lipoproteins","volume":"28","author":"Alipour","year":"2008","unstructured":"Alipour AVan Oostrom AJIzraeljan AVerseyden CCollins JMFrayn KNPlokker TWMElte JWFCastro Cabezas M. Leukocyte activation by triglyceride-rich lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology200828792\u2013797. (https:\/\/doi.org\/10.1161\/ATVBAHA.107.159749)10.1161\/ATVBAHA.107.159749"},{"key":"bib17","series-title":"Atherosclerosis","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.atherosclerosis.2004.07.004","article-title":"Activation of leukocytes by postprandial lipemia in healthy volunteers","volume":"177","author":"Van Oostrom","year":"2004","unstructured":"Van Oostrom AJRabelink TJVerseyden CSijmonsma TPPlokker HWMDe Jaegere PPTCastro Cabezas MC. Activation of leukocytes by postprandial lipemia in healthy volunteers. Atherosclerosis2004177175\u2013182. (https:\/\/doi.org\/10.1016\/j.atherosclerosis.2004.07.004)10.1016\/j.atherosclerosis.2004.07.004"},{"key":"bib18","series-title":"Diabetologia","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s00125-011-2447-3","article-title":"Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and\/or pioglitazone: a randomised double-blind placebo-controlled study","volume":"55","author":"Eliasson","year":"2012","unstructured":"Eliasson BM\u00f6ller-Goede DEeg-Olofsson KWilson CCederholm JFleck PDiamant MTaskinen MRSmith U. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and\/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia201255915\u2013925. (https:\/\/doi.org\/10.1007\/s00125-011-2447-3)10.1007\/s00125-011-2447-3"},{"key":"bib19","series-title":"Atherosclerosis","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.atherosclerosis.2010.04.024","article-title":"One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress","volume":"212","author":"Bunck","year":"2010","unstructured":"Bunck MCCorn\u00e9r AEliasson BHeine RJShaginian RMWu YYan PSmith UYki-J\u00e4rvinen HDiamant MOne-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis2010212223\u2013229. (https:\/\/doi.org\/10.1016\/j.atherosclerosis.2010.04.024)10.1016\/j.atherosclerosis.2010.04.024"},{"key":"bib20","series-title":"Arteriosclerosis, Thrombosis, and Vascular Biology","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1161\/ATVBAHA.118.311339","article-title":"Mechanism of Increased LDL (low-density lipoprotein) and decreased triglycerides with SGLT2 (sodium-glucose cotransporter 2) inhibition","volume":"38","author":"Basu","year":"2018","unstructured":"Basu DHuggins LAScerbo DObunike JMullick AERothenberg PLDi Prospero NAEckel RHGoldberg IJ. Mechanism of Increased LDL (low-density lipoprotein) and decreased triglycerides with SGLT2 (sodium-glucose cotransporter 2) inhibition. Arteriosclerosis, Thrombosis, and Vascular Biology2018382207\u20132216. (https:\/\/doi.org\/10.1161\/ATVBAHA.118.311339)10.1161\/ATVBAHA.118.311339"},{"key":"bib21","series-title":"Atherosclerosis","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.atherosclerosis.2018.02.028","article-title":"SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr\u2212\/\u2212 type 1 diabetic mice","volume":"271","author":"Al-Sharea","year":"2018","unstructured":"Al-Sharea AMurphy AJHuggins LAHu YGoldberg IJNagareddy PR. SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr\u2212\/\u2212 type 1 diabetic mice. Atherosclerosis2018271166\u2013176. (https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.02.028)10.1016\/j.atherosclerosis.2018.02.028"},{"key":"bib22","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1210\/jcem.86.3.7304","article-title":"Clinical review 124: Diabetic dyslipidemia: causes and consequences","volume":"86","author":"Goldberg","year":"2001","unstructured":"Goldberg IJClinical review 124: Diabetic dyslipidemia: causes and consequences. Journal of Clinical Endocrinology and Metabolism200186965\u2013971. (https:\/\/doi.org\/10.1210\/jcem.86.3.7304)10.1210\/jcem.86.3.7304"},{"key":"bib23","series-title":"Arteriosclerosis, Thrombosis, and Vascular Biology","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1161\/01.ATV.0000222015.76038.14","article-title":"Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans","volume":"26","author":"Duez","year":"2006","unstructured":"Duez HLamarche BUffelman KDValero RCohn JSLewis GF. Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans. Arteriosclerosis, Thrombosis, and Vascular Biology2006261357\u20131363. (https:\/\/doi.org\/10.1161\/01.ATV.0000222015.76038.14)10.1161\/01.ATV.0000222015.76038.14"},{"key":"bib24","series-title":"Atherosclerosis","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.atherosclerosis.2015.01.039","article-title":"New insights into the pathophysiology of dyslipidemia in type 2 diabetes","volume":"239","author":"Taskinen","year":"2015","unstructured":"Taskinen MRBor\u00e9n J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis2015239483\u2013495. (https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.01.039)10.1016\/j.atherosclerosis.2015.01.039"},{"key":"bib25","series-title":"Pharmacology and Therapeutics","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.pharmthera.2013.11.008","article-title":"Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment","volume":"141","author":"Varbo","year":"2014","unstructured":"Varbo ABenn MNordestgaard BG. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. Pharmacology and Therapeutics2014141358\u2013367. (https:\/\/doi.org\/10.1016\/j.pharmthera.2013.11.008)10.1016\/j.pharmthera.2013.11.008"},{"key":"bib26","series-title":"Endocrine Reviews","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1210\/er.2018-00184","article-title":"The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk","volume":"40","author":"Sandesara","year":"2019","unstructured":"Sandesara PBVirani SSFazio SShapiro MD. The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk. Endocrine Reviews201940537\u2013557. (https:\/\/doi.org\/10.1210\/er.2018-00184)10.1210\/er.2018-00184"},{"key":"bib27","series-title":"Cardiovascular Diabetology","article-title":"The longitudinal association of remnant cholesterol with cardiovascular outcomes in patients with diabetes and pre-diabetes","volume":"19","author":"Cao","year":"2020","unstructured":"Cao YXZhang HWJin JLLiu HHZhang YGao YGuo YLWu NQHua QLi YFThe longitudinal association of remnant cholesterol with cardiovascular outcomes in patients with diabetes and pre-diabetes. Cardiovascular Diabetology202019 104. (https:\/\/doi.org\/10.1186\/s12933-020-01076-7)"},{"key":"bib28","series-title":"Atherosclerosis","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.atherosclerosis.2015.10.025","article-title":"In vivo evidence for chylomicrons as mediators of postprandial inflammation","volume":"243","author":"de Vries","year":"2015","unstructured":"de Vries MAKlop BAlipour Avan de Geijn GJPrinzen LLiem AHValdivielso PRioja Villodres JRam\u00edrez-Bollero JCastro Cabezas M. In vivo evidence for chylomicrons as mediators of postprandial inflammation. Atherosclerosis2015243540\u2013545. (https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.10.025)10.1016\/j.atherosclerosis.2015.10.025"},{"key":"bib29","series-title":"Diabetes Care","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: a \u2018thrifty substrate\u2019 hypothesis","volume":"39","author":"Ferrannini","year":"2016","unstructured":"Ferrannini EMark MMayoux E. CV protection in the EMPA-REG OUTCOME trial: a \u2018thrifty substrate\u2019 hypothesis. Diabetes Care2016391108\u20131114. (https:\/\/doi.org\/10.2337\/dc16-0330)10.2337\/dc16-0330"},{"key":"bib30","series-title":"Journal of the American College of Cardiology","article-title":"Empagliflozin induces a myocardial metabolic shift from glucose consumption to ketone metabolism that mitigates adverse cardiac remodeling and improves myocardial contractility","volume":"71","author":"Santos-Gallego","year":"2018","unstructured":"Santos-Gallego CGIbanez JARAntonio RSIshikawa KWatanabe SPicatoste Botija MBSalvo AJSHajjar RFuster VBadimon J. Empagliflozin induces a myocardial metabolic shift from glucose consumption to ketone metabolism that mitigates adverse cardiac remodeling and improves myocardial contractility. Journal of the American College of Cardiology201871 A674. (https:\/\/doi.org\/10.1016\/S0735-1097(1831215-4)"},{"key":"bib31","series-title":"Journal of Lipid Research","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/S0022-2275(20)32015-0","article-title":"In vivo evidence of defective postprandial and postabsorptive free fatty acid metabolism in familial combined hyperlipidemia","volume":"41","author":"Meijssen","year":"2000","unstructured":"Meijssen SCastro Cabezas MCTwickler TBJansen HErkelens DW. In vivo evidence of defective postprandial and postabsorptive free fatty acid metabolism in familial combined hyperlipidemia. Journal of Lipid Research2000411096\u20131102. (https:\/\/doi.org\/10.1016\/S0022-2275(2032015-0)10.1016\/S0022-2275(20)32015-0"},{"key":"bib32","series-title":"Best Practice and Research: Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.beem.2005.07.004","article-title":"Human fat cell lipolysis: biochemistry, regulation and clinical role","volume":"19","author":"Arner","year":"2005","unstructured":"Arner PHuman fat cell lipolysis: biochemistry, regulation and clinical role. Best Practice and Research: Clinical Endocrinology and Metabolism200519471\u2013482. (https:\/\/doi.org\/10.1016\/j.beem.2005.07.004)10.1016\/j.beem.2005.07.004"},{"key":"bib33","series-title":"Diabetes Therapy","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s13300-018-0366-8","article-title":"Effects of Ipragliflozin on postprandial glucose metabolism and gut peptides in type 2 diabetes: a pilot study","volume":"9","author":"Ueno","year":"2018","unstructured":"Ueno HNakazato HEbihara ENoma KKawano TNagamine KSakoda HNakazato M. Effects of Ipragliflozin on postprandial glucose metabolism and gut peptides in type 2 diabetes: a pilot study. Diabetes Therapy20189403\u2013411. (https:\/\/doi.org\/10.1007\/s13300-018-0366-8)10.1007\/s13300-018-0366-8"},{"key":"bib34","series-title":"Diabetes","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2337\/db10-0763","article-title":"Effects of acute hyperglucagonemia on hepatic and intestinal lipoprotein production and clearance in healthy humans","volume":"60","author":"Xiao","year":"2011","unstructured":"Xiao CPavlic MSzeto LPatterson BWLewis GF. Effects of acute hyperglucagonemia on hepatic and intestinal lipoprotein production and clearance in healthy humans. Diabetes201160383\u2013390. (https:\/\/doi.org\/10.2337\/db10-0763)10.2337\/db10-0763"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/186\/5\/EJE-21-1270.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eje.bioscientifica.com\/downloadpdf\/journals\/eje\/186\/5\/EJE-21-1270.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/eje.bioscientifica.com\/downloadpdf\/journals\/eje\/186\/5\/EJE-21-1270.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:17:47Z","timestamp":1676391467000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/186\/5\/597\/6853693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,1]]},"references-count":34,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.1530\/eje-21-1270","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,1]]}}}